Conference Proceedings
Lorlatinib in patients with ALK plus NSCLC treated beyond initial disease progression
SI Ou, B Solomon, A Shaw, SM Gadgeel, B Besse, RA Soo, A Abbattista, H Thurm, F Toffalorio, RJ Wiltshire, A Bearz
Annals of Oncology | ELSEVIER | Published : 2020
Grants
Funding Acknowledgements
Pfizer Inc.